Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGN-259 in neurotrophic keratopathy
NCT05555589Phase 3Recruiting
- Sponsor
- ReGenTree
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Peptides
- Countries
- 4
01
Overview
A Phase 3 trial of timbetasin in neurotrophic keratopathy (NK), sponsored by ReGenTree. Started Apr 2023; status: recruiting.
02
Drugs
timbetasin
03
Conditions
neurotrophic keratopathy (NK)
Beyond the preview
Go deeper on NCT05555589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555589.